Opioid agonist treatment take-home doses (‘carries’): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?

Opioid agonist treatment take-home doses (‘carries’): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?

Abstract Opioid agonist treatment (OAT) is the primary intervention for opioid use disorder (OUD) in Canada and the USA. Yet, a number of barriers contribute to sub-optimal treatment uptake and retention, including daily-supervised medication administration. Thus, clients are eventually granted acce...

Full description

Bibliographic Details
Main Authors: Cayley Russell, Shannon Lange, Fiona Kouyoumdjian, Amanda Butler, Farihah Ali
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Harm Reduction Journal
Subjects:
Carries
Corrections
High-risk populations
Opioids
Opioid use disorder
Opioid agonist treatment
Online Access:https://doi.org/10.1186/s12954-022-00671-z

Internet

https://doi.org/10.1186/s12954-022-00671-z

Similar Items